ОПТИМИЗАЦИЯ ЗАТРАТ НА ЛЕКАРСТВЕННУЮ ТЕРАПИЮ COVID-19 НА ОСНОВЕ ФАРМАКОЭКОНОМИЧЕСКОГО АНАЛИЗА

Abstract

Abstract. COVID-19, a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was first reported in China in December 2019. Economically, the spread of COVID-19, the ever-increasing number of patients, and complications of the disease have resulted in high direct medical and indirect costs to patients, the healthcare system, and the government as a whole. Direct medical costs vary depending on the number of patients, disease severity, average length of hospital stay and other factors. The aim of the study was to identify ways to optimize COVID-19 drug therapy costs using pharmacoeconomic analysis methods. Case histories of 334 patients treated in a reassigned infectious disease unit of a hospital with a diagnosis of Covid-19 novel coronavirus infection were analyzed. 80% of the medical organization's costs were for 8 medications (5.6%): levilimab, baricitinib, olokizumab, heparin, dalteparin, levofloxacin, cefotaxime+sulbactam, and propofol. Comparative analysis of the cost of drug therapy with the recommended treatment regimens of the Temporary Methodological Recommendations of the Ministry of Health of the Russian Federation showed that only when using the scheme № 2 for a moderate course of the disease and the choice of the cheapest drugs, the cost of completed cases covers the cost of treatment of patients, other treatment regimens for medical organization are economically unjustified. The cost of therapy with these drugs exceeds the cost of paid cases depending on the scheme and variant from 65% to 198%. The study aims to assess the cost of clinical management of patients hospitalized with COVID-19, depending on their severity, by examining the resources used to provide medical care.